59831 Convection-Enhanced Delivery of Topotecan Induces IL-1β-Associated Inflammation in Glioblastoma
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
INTRODUCTION: In our clinical trial using convection-enhanced delivery (CED) of topotecan (TPT) in patients with glioblastoma, CED TPT effectively reduced proliferating tumor cells. However, all patients ultimately experienced recurrence, and post-treatment tissue exhibited increased inflammatory cytokines and mesenchymal signatures. One of the most upregulated inflammatory cytokines, IL-1β, is associated with poor survival in glioblastoma. Further, local antagonism of IL-1β has been shown to prolong survival in tumor-bearing mice. METHODS: We conducted in vitro studies using human glioma and microglia cell lines, in monoculture and coculture, and measured IL-1β expression using qPCR and ELISA. We also performed single-cell RNA sequencing (scRNA-seq) on acute human glioblastoma slices treated with TPT ex vivo. Finally, we analyzed IL-1β expression following CED TPT treatment using scRNA-seq in a syngeneic mouse glioma model. RESULTS: GSEA using bulk RNA sequencing data from the CED TPT clinical trial demonstrated a trend toward upregulation of the IL-1 family signaling reactome (NES = 1.57, p = 0.06). In vitro, TPT treatment of glioma-microglia cocultures resulted in significant IL-1β upregulation at both mRNA and protein levels. Acute human glioblastoma slices treated with TPT ex vivo demonstrated increased IL-1β expression in a subpopulation of myeloid cells. Seven-day CED TPT treatment led to significant upregulation of IL-1β, predominantly in myeloid cells. CONCLUSIONS: TPT treatment induces IL-1β expression across in vitro and ex vivo glioblastoma models, as well as in vivo CED-treated tumors, with myeloid cells as a primary source. These findings support further investigation into the role of IL-1β in mediating TPT-induced inflammation in glioma. We are currently planning experiments to test the therapeutic potential of IL-1β blockade, such as with anakinra, as an adjunct to TPT treatment to reduce pro-tumor inflammation and improve outcomes in glioblastoma.
Fields of Study & Subjects
Glioma Diagnosis and Treatment
Neuroinflammation and Neurodegeneration Mechanisms
Cancer Immunotherapy and Biomarkers
Publication details
- Journal / source
- Neurosurgery
- Volume
- 72
- Issue
- Supplement_1
- Pages
- 312–313
- Publication date
- 26 March 2026
- Language
- EN